Search clinical trials for: Randomized, double-blind, placebo-controlled, single-dose subcutaneous administration study

Total 125675 results

The First Affiliated Hospital with Nanjing Medical...
Huai'an First People's Hospital; Yancheng First People's Hospital

Recruiting

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

Acute Myeloid Leukemia

China
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Stephanie B. Seminara, MD

Recruiting

Kisspeptin Administration Subcutaneously to Patients With IHH

Hypogonadotropic Hypogonadism

United States
Stephanie B. Seminara, MD

Recruiting

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders (KASPR)

Hypogonadotropic Hypogonadism | Hypothalamic Amenorrhea

United States
Ashvattha Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (AMD) or Subjects With Diabetic Macular Edema (DME) (Tejas)

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

United States
Groupe d'Etude Therapeutique des Affections Inflammatoires...
Takeda

Recruiting

VeDOlizumab PERsistence in IBD Patients After Switching From Intravenous to Subcutaneous Administration : a Real-life Multicenter Study (DOPER) (DOPER)

Inflammatory Bowel Diseases

France
Amgen

Recruiting

A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients

B Cell Precursor Acute Lymphoblastic Leukemia

Japan, Australia, Spain, United States, Italy, Germany, France, Turkey, Canada, Netherlands, Austria
University Hospital, Caen

Recruiting

Paracetamol Route in Palliative Care Patients (PARASCIVPALLIA) (PARASCIVPALL)

Palliative Care

France
Heidelberg University

Recruiting

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF (ANAKIN)

Cystic Fibrosis, 10011762

Germany
AstraZeneca

Active, not recruiting

A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers

Healthy Participants

Germany
Janssen Research & Development, LLC

Active, not recruiting

A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies (PALOMA)

Advanced Solid Malignancies

United States, United Kingdom, Canada, Korea, Republic of
Hoffmann-La Roche

Active, not recruiting

A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis

Multiple Sclerosis (MS)

United States
NeuroDerm Ltd.

Completed

A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patients

Parkinson's Disease

Israel
CSL Behring

Active, not recruiting

Respreeza® Self-administration and Learning Program (AmAREtTI Study) (AmAREtTI)

Alpha-1 Antitrypsin Deficiency

France
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

Inflammatory Breast Cancer | Early Breast Cancer | Locally Advanced Breast Cancer

Canada, Croatia, Spain, Argentina, Mexico, Korea, Republic of, Bosnia and Herzegovina, Brazil, Costa Rica, Turkey, Singapore, Bulgaria, South Africa, India, Peru, Kenya, Chile
Ensol Bioscience

Completed

Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects

Healthy

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Spain, Netherlands, Sweden, Denmark, France
Hoffmann-La Roche

Active, not recruiting

A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer

HER2-positive Early Breast Cancer

China
Janssen Research & Development, LLC

Completed

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Canada, United States, Czechia, Israel, Italy, Korea, Republic of, Brazil, United Kingdom, Japan, Taiwan, Australia, Poland, Spain, France, Russian Federation, Sweden, Ukraine, Greece
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
Amgen

Completed

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States, Australia, Italy, United Kingdom, Germany, France
Amphastar Pharmaceuticals, Inc.

Completed

Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004) and NovoLog After Single-Dose Subcutaneous Administration to Healthy Volunteers

Pharmacokinetics | Pharmacodynamics

United States
Oneness Biotech Co., Ltd.

Active, not recruiting

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Atopic Dermatitis

United States
NeuroDerm Ltd.

Completed

Study of Subcutaneous Continuous Administration of Levodopa/Carbidopa Solution (ND0612) in Healthy Volunteers

Parkinson's Disease

Israel
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Localized Resectable Neuroblastoma | Localized Unresectable Neuroblastoma | Regional Neuroblastoma | Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 4 Neuroblastoma

United States
Hoffmann-La Roche

Completed

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer (PHranceSCa)

HER2-Positive Early Breast Cancer

United States, Finland, Hong Kong, Panama, Portugal, Spain, Mexico, Sweden, Brazil, Serbia, Argentina, Lebanon, Cuba, Qatar, Saudi Arabia, Chile, Jordan
Ionis Pharmaceuticals, Inc.

Completed

A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled Hypertension

Hypertension

United States
Novartis Pharmaceuticals

Completed

Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

Melanoma | Non-Small Cell Lung Cancer | Advanced Cancer

Canada, United States, Australia, France, Italy, Spain, Finland, Germany, Norway, Poland, Sweden
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Completed

Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects

Healthy

United States
Biogen

Active, not recruiting

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Multiple Sclerosis

United States
University of Florida

Completed

Skeletal Muscle and Adipose Tissue Study

Idiopathic Scoliosis

United States
AstraZeneca
Parexel

Completed

A First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD2373 After Single Dose Administration in Healthy Male Subjects of African Ancestry.

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer (FeDeriCa)

Early Breast Cancer

France, Spain, United States, Korea, Republic of, Canada, United Kingdom, Argentina, Belgium, Germany, Italy, Taiwan, Thailand, Japan, Brazil, Mexico, Czechia, Poland, Russian Federation, Ukraine
Cidara Therapeutics Inc.
Janssen Pharmaceuticals

Active, not recruiting

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

Healthy

United States
Alnylam Pharmaceuticals

Completed

Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

TTR-mediated Amyloidosis

United States, United Kingdom
Amgen

Completed

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

Rheumatoid Arthritis

United States, Germany, Italy, Mexico, France, Canada, Hungary, Portugal, Spain, Greece, Bulgaria, Czechia, Poland, Argentina, South Africa
scPharmaceuticals, Inc.

Completed

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

Heart Failure

United States
GlaxoSmithKline

Completed

Repeat Dose Subcutaneous Rhumatoid Arthritis Efficacy Study

Arthritis, Rheumatoid

Russian Federation
Ashvattha Therapeutics, Inc.

Completed

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

Diabetic Macular Edema | Neovascular Age-related Macular Degeneration

Australia
Genentech, Inc.

Approved for marketing

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

HER2-positive Breast Cancer

United States
AbbVie

Completed

Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy Participants

Healthy Volunteers

United States
Hoffmann-La Roche

Completed

Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis

Juvenile Idiopathic Arthritis

United States, Canada, United Kingdom, Brazil, Germany, Italy, Russian Federation, Spain, Australia, France, Mexico, Argentina
Teva Branded Pharmaceutical Products R&D, Inc.
FHI 360

Completed

A Study to Evaluate Injection Pain and Local Tolerability Following Subcutaneous (SC) Administration of TV-46046

Contraception

Dominican Republic
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Healthy

Australia
SQ Innovation, Inc.
Accel Clinical Services

Completed

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

Heart Failure

United States
Shire
Halozyme Therapeutics

Completed

A Study to Evaluate the Safety and Pharmacology of Subcutaneous Administration of CINRYZE With Recombinant Human Hyaluronidase

Hereditary Angioedema

United States
Shire

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CINRYZE Administration

Hereditary Angioedema

United States
GlaxoSmithKline

Completed

Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome

Sjogren's Syndrome

Spain, France, Germany, Netherlands, United Kingdom, Sweden, Argentina, Italy, Canada, Norway
Pfizer

Terminated

A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections

Osteoarthritis, Knee | Osteoarthritis, Hip

United States

3

Subscribe